Cogent Biosciences Inc
Cogent Biosciences Inc (COGT) Covered Calls
Cogent Biosciences Inc trades in the Biotechnology industry with an IV Rank of 84.52%, high versus the past year. COGT's highest covered call setup is the $40.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 43.63% out of the money with 3 days to expiration, a 43.81% return until expiration, and a 5,329.74% theoretical annualized return. Across the setups shown, annualized returns run from 138.83% to 5,329.74% at strikes between $31.00 and $45.00, with 3 to 59 days to expiration, as of Nov 17, 2026.
Read more
Running COGT covered calls helps you generate income from Cogent Biosciences Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best COGT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If COGT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling COGT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given COGT covered call is worth writing.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc.
| 2026-11-20 | 3 | 40.00 | 43.63 | 0.05 | 4.90 | 1220.00 | 43.81 | 5329.74 | -0.18 | +0.33 | 1,105 | 4.85 |
| 2026-12-18 | 31 | 45.00 | 61.58 | 0.05 | 4.80 | 1720.00 | 61.76 | 727.17 | -0.18 | +0.31 | 8 | 4.75 |
| 2026-12-18 | 31 | 40.00 | 43.63 | 0.05 | 1.35 | 1220.00 | 43.81 | 515.78 | -0.18 | +0.17 | 628 | 1.30 |
| 2026-12-18 | 31 | 35.00 | 25.67 | 0.40 | 1.75 | 755.00 | 27.11 | 319.19 | -1.44 | +0.26 | 2,586 | 1.35 |
| 2027-01-15 | 59 | 40.00 | 43.63 | 0.10 | 1.45 | 1225.00 | 43.99 | 272.11 | -0.36 | +0.18 | 724 | 1.35 |
| 2026-12-18 | 31 | 33.00 | 18.49 | 0.25 | 1.85 | 540.00 | 19.39 | 228.30 | -0.90 | +0.28 | 412 | 1.60 |
| 2026-12-18 | 31 | 32.00 | 14.90 | 0.05 | 4.50 | 420.00 | 15.08 | 177.56 | -0.18 | +0.41 | 47 | 4.45 |
| 2027-01-15 | 59 | 35.00 | 25.67 | 0.45 | 1.85 | 760.00 | 27.29 | 168.82 | -1.62 | +0.27 | 629 | 1.40 |
| 2026-12-18 | 31 | 31.00 | 11.31 | 0.25 | 4.80 | 340.00 | 12.21 | 143.74 | -0.90 | +0.44 | 6 | 4.55 |
| 2027-01-15 | 59 | 34.00 | 22.08 | 0.10 | 4.80 | 625.00 | 22.44 | 138.83 | -0.36 | +0.39 | 3 | 4.70 |
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank84.52% High
- Market cap (M$)4,839
- 52 weeks high-36.41%
- 52 weeks low5.50%
- Analyst recommendationStrong Buy
1.17 - Target price$55.82
101.30% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2027-02-16
- P/E—
- Future P/E—
- EPS (ttm)-2.50
- EPS growth next 5 years—
As of Nov 18, 2026